237 related articles for article (PubMed ID: 23908443)
1. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.
Ferucci ED; Darrah E; Smolik I; Choromanski TL; Robinson DB; Newkirk MM; Fritzler MJ; Rosen A; El-Gabalawy HS
J Rheumatol; 2013 Sep; 40(9):1523-8. PubMed ID: 23908443
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
Umeda N; Matsumoto I; Kawaguchi H; Kurashima Y; Kondo Y; Tsuboi H; Ogishima H; Suzuki T; Kagami Y; Sakyu T; Ishigami A; Maruyama N; Sumida T
Clin Rheumatol; 2016 May; 35(5):1181-8. PubMed ID: 26415740
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
4. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model.
Auger I; Balandraud N; Massy E; Hemon MF; Peen E; Arnoux F; Mariot C; Martin M; Lafforgue P; Busnel JM; Roudier J
Arthritis Rheumatol; 2020 Jun; 72(6):903-911. PubMed ID: 31820586
[TBL] [Abstract][Full Text] [Related]
5. Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
Cappelli LC; Konig MF; Gelber AC; Bingham CO; Darrah E
Arthritis Res Ther; 2018 Mar; 20(1):59. PubMed ID: 29566742
[TBL] [Abstract][Full Text] [Related]
6. Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis.
Poór G; Nagy ZB; Schmidt Z; Brózik M; Merétey K; Gergely P
Ann N Y Acad Sci; 2007 Sep; 1110():23-32. PubMed ID: 17911417
[TBL] [Abstract][Full Text] [Related]
7. Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study.
Bang SY; Han TU; Choi CB; Sung YK; Bae SC; Kang C
Arthritis Res Ther; 2010; 12(3):R115. PubMed ID: 20537173
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.
Darrah E; Giles JT; Davis RL; Naik P; Wang H; Konig MF; Cappelli LC; Bingham CO; Danoff SK; Andrade F
Front Immunol; 2018; 9():2696. PubMed ID: 30515171
[No Abstract] [Full Text] [Related]
9. Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
Navarro-Millán I; Darrah E; Westfall AO; Mikuls TR; Reynolds RJ; Danila MI; Curtis JR; ; Rosen A; Bridges SL
Arthritis Res Ther; 2016 Oct; 18(1):241. PubMed ID: 27770831
[TBL] [Abstract][Full Text] [Related]
10. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
[TBL] [Abstract][Full Text] [Related]
11. Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives.
El-Gabalawy HS; Robinson DB; Hart D; Elias B; Markland J; Peschken CA; Smolik I; Montes-Aldana G; Schroeder M; Fritzler MJ; Cheang M; Oen K
J Rheumatol; 2009 Jun; 36(6):1130-5. PubMed ID: 19411392
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis.
Zhao J; Zhao Y; He J; Jia R; Li Z
J Rheumatol; 2008 Jun; 35(6):969-74. PubMed ID: 18398945
[TBL] [Abstract][Full Text] [Related]
13. Anti-citrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity.
Umeda N; Matsumoto I; Ito I; Kawasaki A; Tanaka Y; Inoue A; Tsuboi H; Suzuki T; Hayashi T; Ito S; Tsuchiya N; Sumida T
Clin Exp Immunol; 2013 Apr; 172(1):44-53. PubMed ID: 23480184
[TBL] [Abstract][Full Text] [Related]
14. Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients.
El-Gabalawy HS; Robinson DB; Smolik I; Hart D; Elias B; Wong K; Peschken CA; Hitchon CA; Li X; Bernstein CN; Newkirk MM; Fritzler MJ
Arthritis Rheum; 2012 Jun; 64(6):1720-9. PubMed ID: 22354869
[TBL] [Abstract][Full Text] [Related]
15. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles.
Irigoyen P; Lee AT; Wener MH; Li W; Kern M; Batliwalla F; Lum RF; Massarotti E; Weisman M; Bombardier C; Remmers EF; Kastner DL; Seldin MF; Criswell LA; Gregersen PK
Arthritis Rheum; 2005 Dec; 52(12):3813-8. PubMed ID: 16320316
[TBL] [Abstract][Full Text] [Related]
16. Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis.
Snir O; Gomez-Cabrero D; Montes A; Perez-Pampin E; Gómez-Reino JJ; Seddighzadeh M; Klich KU; Israelsson L; Ding B; Catrina AI; Holmdahl R; Alfredsson L; Klareskog L; Tegnér J; Gonzalez A; Malmström V; Padyukov L
Arthritis Res Ther; 2014 Aug; 16(4):414. PubMed ID: 25138370
[TBL] [Abstract][Full Text] [Related]
17. Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate.
Pollmann S; Stensland M; Halvorsen EH; Sollid LM; Kvien TK; Fleckenstein B; Molberg O
Rheumatol Int; 2012 May; 32(5):1271-6. PubMed ID: 21267570
[TBL] [Abstract][Full Text] [Related]
18. Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
Shi J; Darrah E; Sims GP; Mustelin T; Sampson K; Konig MF; Bingham CO; Rosen A; Andrade F
Ann Rheum Dis; 2018 Jan; 77(1):141-148. PubMed ID: 29070531
[TBL] [Abstract][Full Text] [Related]
19. Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls.
Koppejan H; Trouw LA; Sokolove J; Lahey LJ; Huizinga TJ; Smolik IA; Robinson DB; El-Gabalawy HS; Toes RE; Hitchon CA
Arthritis Rheumatol; 2016 Sep; 68(9):2090-8. PubMed ID: 26946484
[TBL] [Abstract][Full Text] [Related]
20. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies.
Jiang X; Trouw LA; van Wesemael TJ; Shi J; Bengtsson C; Källberg H; Malmström V; Israelsson L; Hreggvidsdottir H; Verduijn W; Klareskog L; Alfredsson L; Huizinga TW; Toes RE; Lundberg K; van der Woude D
Ann Rheum Dis; 2014 Oct; 73(10):1761-8. PubMed ID: 24812286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]